Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.52 USD | -2.95% | +12.15% | -3.93% |
30/04 | Guggenheim Starts Precision BioSciences With Buy Rating, $19 Price Target | MT |
16/04 | Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 705.4 | 437.7 | 449.7 | 132 | 44.5 | 72.76 | - | - |
Enterprise Value (EV) 1 | 524.5 | 347.9 | 308.5 | -35.31 | 44.5 | 10.33 | -62.15 | -106.8 |
P/E ratio | -6.29 x | -3.99 x | -14.2 x | -0.94 x | -0.69 x | -1.38 x | -1.9 x | -2.16 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 31.7 x | 18 x | 3.89 x | 5.26 x | 0.91 x | 3.09 x | 3.51 x | 3.15 x |
EV / Revenue | 23.6 x | 14.3 x | 2.67 x | -1.41 x | 0.91 x | 0.44 x | -3 x | -4.62 x |
EV / EBITDA | -6.41 x | -3.44 x | -10.1 x | 0.38 x | -1.21 x | -0.26 x | 1.41 x | 1.79 x |
EV / FCF | -5.48 x | -3.76 x | -19.4 x | 0.72 x | - | -0.16 x | 0.87 x | 1.39 x |
FCF Yield | -18.2% | -26.6% | -5.16% | 139% | - | -629% | 115% | 72.1% |
Price to Book | 5.14 x | 9.77 x | 4.76 x | - | - | - | - | - |
Nbr of stocks (in thousands) | 1,693 | 1,749 | 2,026 | 3,699 | 4,064 | 6,916 | - | - |
Reference price 2 | 416.7 | 250.2 | 222.0 | 35.70 | 10.95 | 10.52 | 10.52 | 10.52 |
Announcement Date | 10/03/20 | 18/03/21 | 15/03/22 | 09/03/23 | 27/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 22.24 | 24.28 | 115.5 | 25.1 | 48.73 | 23.57 | 20.72 | 23.12 |
EBITDA 1 | -81.89 | -101.1 | -30.42 | -92.57 | -36.92 | -40.09 | -44.21 | -59.54 |
EBIT 1 | -87.2 | -109.8 | -39.4 | -100.4 | -43.74 | -60.19 | -70.82 | -80 |
Operating Margin | -392.14% | -452.25% | -34.11% | -399.9% | -89.76% | -255.36% | -341.85% | -346.11% |
Earnings before Tax (EBT) 1 | -92.88 | -109 | -30.6 | -111.6 | -61.32 | -51.36 | -66.36 | -75.3 |
Net income 1 | -92.88 | -109 | -30.6 | -111.6 | -61.32 | -51.36 | -66.36 | -75.3 |
Net margin | -417.65% | -448.86% | -26.49% | -444.8% | -125.84% | -217.91% | -320.31% | -325.75% |
EPS 2 | -66.30 | -62.70 | -15.60 | -38.10 | -15.96 | -7.597 | -5.542 | -4.874 |
Free Cash Flow 1 | -95.68 | -92.42 | -15.91 | -49.07 | - | -65 | -71.5 | -77 |
FCF margin | -430.26% | -380.55% | -13.77% | -195.52% | - | -275.76% | -345.13% | -333.12% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 10/03/20 | 18/03/21 | 15/03/22 | 09/03/23 | 27/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 24.04 | 6.339 | 3.317 | 3.82 | 7.363 | 10.6 | 8.78 | 19.79 | 13.12 | 7.038 | 6.021 | 6.988 | 6.654 | 6.988 | 10 |
EBITDA 1 | -9.278 | -28.58 | -25.38 | -27.67 | -20.99 | -18.53 | -22.51 | -10.02 | -10.74 | -13.61 | -6.3 | -12.1 | -12.7 | -12.3 | - |
EBIT 1 | -11.54 | -30.75 | -27.35 | -29.6 | -22.93 | -20.49 | -24.46 | -11.99 | -12.36 | -14.89 | -13.92 | -13.42 | -14.19 | -14.51 | - |
Operating Margin | -48.02% | -485.09% | -824.42% | -774.9% | -311.42% | -193.33% | -278.63% | -60.57% | -94.23% | -211.57% | -231.21% | -192.07% | -213.21% | -207.69% | - |
Earnings before Tax (EBT) 1 | -11.28 | -22.29 | -28.17 | -31.04 | -23.95 | -17.22 | -25.06 | -11.89 | -12.11 | -16.29 | -12.76 | -12.17 | -13.09 | -13.39 | - |
Net income 1 | -11.28 | -22.29 | -28.17 | -31.04 | -23.95 | -17.22 | -25.06 | -11.89 | -8.079 | -16.29 | -12.76 | -12.17 | -13.09 | -13.39 | - |
Net margin | -46.93% | -351.63% | -849.2% | -812.43% | -325.22% | -162.46% | -285.42% | -60.09% | -61.58% | -231.44% | -211.93% | -174.15% | -196.7% | -191.62% | - |
EPS 2 | -5.700 | -11.40 | -13.80 | -13.80 | -6.600 | -6.900 | -6.900 | -3.000 | -2.100 | -15.56 | -1.913 | -1.825 | -1.907 | -1.697 | -0.8500 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 10/11/21 | 15/03/22 | 09/05/22 | 08/08/22 | 08/11/22 | 09/03/23 | 09/05/23 | 04/08/23 | 07/11/23 | 27/03/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 181 | 89.8 | 141 | 167 | - | 62.4 | 135 | 180 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | -95.7 | -92.4 | -15.9 | -49.1 | - | -65 | -71.5 | -77 |
ROE (net income / shareholders' equity) | -104% | -119% | -57.7% | - | - | - | - | - |
ROA (Net income/ Total Assets) | -49.7% | -56.6% | -21.6% | - | - | - | - | - |
Assets 1 | 186.9 | 192.7 | 141.4 | - | - | - | - | - |
Book Value Per Share | 81.10 | 25.60 | 46.60 | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 24.7 | 5.03 | 5.05 | 3.32 | - | 2.62 | 2.64 | 3 |
Capex / Sales | 110.92% | 20.72% | 4.37% | 13.22% | - | 11.1% | 12.73% | 12.98% |
Announcement Date | 10/03/20 | 18/03/21 | 15/03/22 | 09/03/23 | 27/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
- Stock Market
- Equities
- DTIL Stock
- Financials Precision BioSciences, Inc.